Literature DB >> 14573609

Secretion of heparanase protein is regulated by glycosylation in human tumor cell lines.

Siro Simizu1, Keisuke Ishida, Michal K Wierzba, Hiroyuki Osada.   

Abstract

The endo-beta-d-glucuronidase, heparanase, is capable of specifically degrading heparan sulfate, and this activity is associated with the metastatic potential of tumor cells. The predicted amino acid sequence of heparanase includes six putative N-glycosylation sites; however, the precise biochemical role of glycosylated heparanase remains unknown. In this study, we examined the link between glycosylation and the function of heparanase in human tumor cell lines. Heparanase protein was glycosylated at six Asn residues in human tumor cell lines. Treatment with a glycosylation inhibitor demonstrated that glycosylation was not required for the activity of heparanase. However, glycosylation affected the kinetics of endoplasmic reticulum-to-Golgi transport and of secretion of the enzyme.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14573609     DOI: 10.1074/jbc.M300541200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

1.  Adaptive evolution of heparanase in hypoxia-tolerant Spalax: gene cloning and identification of a unique splice variant.

Authors:  Nicola J Nasser; Eviatar Nevo; Itay Shafat; Neta Ilan; Israel Vlodavsky; Aaron Avivi
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-04       Impact factor: 11.205

2.  Antisense-mediated suppression of Heparanase gene inhibits melanoma cell invasion.

Authors:  Madhuchhanda Roy; Jane Reiland; Brian P Murry; Vladimir Chouljenko; Konstantin G Kousoulas; Dario Marchetti
Journal:  Neoplasia       Date:  2005-03       Impact factor: 5.715

3.  Dpy-19 like 3-mediated C-mannosylation and expression levels of RPE-spondin in human tumor cell lines.

Authors:  Shohei Morishita; Takehiro Suzuki; Yuki Niwa; Naoshi Dohmae; Siro Simizu
Journal:  Oncol Lett       Date:  2017-06-22       Impact factor: 2.967

4.  Heparanase 2 interacts with heparan sulfate with high affinity and inhibits heparanase activity.

Authors:  Flonia Levy-Adam; Sari Feld; Victoria Cohen-Kaplan; Anna Shteingauz; Miriam Gross; Gil Arvatz; Inna Naroditsky; Neta Ilan; Ilana Doweck; Israel Vlodavsky
Journal:  J Biol Chem       Date:  2010-06-24       Impact factor: 5.157

5.  A novel human heparanase splice variant, T5, endowed with protumorigenic characteristics.

Authors:  Uri Barash; Victoria Cohen-Kaplan; Gil Arvatz; Svetlana Gingis-Velitski; Flonia Levy-Adam; Ofer Nativ; Ronen Shemesh; Michal Ayalon-Sofer; Neta Ilan; Israel Vlodavsky
Journal:  FASEB J       Date:  2009-12-09       Impact factor: 5.191

6.  Low and high affinity receptors mediate cellular uptake of heparanase.

Authors:  Olga Ben-Zaken; Itay Shafat; Svetlana Gingis-Velitski; Haim Bangio; Idil Kasuto Kelson; Tal Alergand; Yehudit Amor; Ruth Ben-Yakar Maya; Israel Vlodavsky; Neta Ilan
Journal:  Int J Biochem Cell Biol       Date:  2007-09-29       Impact factor: 5.085

7.  Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment.

Authors:  Ghada Abboud-Jarrous; Ruth Atzmon; Tamar Peretz; Carmela Palermo; Bedrick B Gadea; Johanna A Joyce; Israel Vlodavsky
Journal:  J Biol Chem       Date:  2008-04-30       Impact factor: 5.157

8.  Small RNA interference-mediated gene silencing of heparanase abolishes the invasion, metastasis and angiogenesis of gastric cancer cells.

Authors:  Liduan Zheng; Guosong Jiang; Hong Mei; Jiarui Pu; Jihua Dong; Xiaohua Hou; Qiangsong Tong
Journal:  BMC Cancer       Date:  2010-02-05       Impact factor: 4.430

9.  Two heparanase splicing variants with distinct properties are necessary in early Xenopus development.

Authors:  Gabriel E Bertolesi; George Michaiel; Sarah McFarlane
Journal:  J Biol Chem       Date:  2008-04-07       Impact factor: 5.157

Review 10.  Heparanase: a target for drug discovery in cancer and inflammation.

Authors:  E A McKenzie
Journal:  Br J Pharmacol       Date:  2007-03-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.